Nexalin Technology, Inc. (NXL) Stock Score, Valuation & Financial Research
Nexalin Technology, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for NXL
Nexalin Technology, Inc. currently has a Wall Street Score of 29/100. The stored market price is $4.85. Its financial score is 26/100. Its valuation score is 0/100. The latest WSS change is +1.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What Nexalin Technology, Inc. does
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
NXL financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $4.85
- Market capitalization:
- $3.6M
- Revenue:
- $217K
- Net income:
- $-9.0M
- Free cash flow:
- $-5.0M
- Cash:
- $1.0M
- Total debt:
- $0
- EPS:
- -14.40
- Financial score:
- 26/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is -0.3%.
- Free cash flow is $-5.0M, showing cash burn in the current stored period.
- The balance sheet shows $1.0M of cash versus $0 of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +1.4 points: NXL increased 1.4 points because Asset improved by 15.5 points, Buffett improved by 2.4 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 26/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research NXL
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.